|
|
|
Overview
Concert Pharmaceuticals is a clinical stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert applies its proprietary DCE Platform (deuterated chemical entity) to approved drugs and other agents with known human pharmacological activity to create novel medicines with the potential for enhanced efficacy, better tolerability and improved safety. By leveraging the large body of knowledge on known drugs, Concert focuses its efforts on valuable opportunities where deuterium modification may provide important medical benefits.
Media Contact:
Justine Koenigsberg
Senior Director, Corporate Communications and Investor Relations
781.674.5284
IR@concertpharma.com
Concert Materials and Related Stories
Media Feature

Healthcare Global June 2011
Concert
Pharmaceuticals Changes the Industry with Deuterium
Concert Publications
The following is a selection of news stories in which Concert is featured:
- July 2011, Boston Business Journal, "Roger Tung: In it for long haul as CEO of Concert Pharmaceuticals"
- June 2011, Xconomy, "Concert Pharmaceuticals Hits $4 Million Milestone in GSK Alliance"
- March 2011, Drug Discovery News, "In the Army Now"
- December 2010, Mass High Tech, "Federal Grants Boost Several Mass. Diabetes-Focused Companies"
- November 2010, Boston Business Journal,
Mass. wins biotech tax credits
Archive of news stories
Awards and Recognition
[ back to top ]
|
|